(vianews) - shares of erytech pharma (cac 40: eryp.pa) jumped by a staggering 33.43% in 21 sessions from €0.68 to €0.91 at 20:52 est on tuesday, after five consecutive sessions in a row of gains. cac 40 is rising 0.47% to €7,533.63, following the last session's downward trend.
erytech pharma's last close was €0.93, 58.67% below its 52-week high of €2.26.
about erytech pharma
erytech pharma s.a., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in france and the united states. it develops eryaspase, which is in phase 3 clinical development for the treatment of second-line pancreatic cancer, and in phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. the company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. erytech pharma s.a. was incorporated in 2004 and is headquartered in lyon, france.
earnings per share
as for profitability, erytech pharma has a trailing twelve months eps of €-0.01.
volatility
erytech pharma's last week, last month's, and last quarter's current intraday variation average was 2.73%, 1.21%, and 5.34%.
erytech pharma's highest amplitude of average volatility was 2.73% (last week), 3.14% (last month), and 5.34% (last quarter).
revenue growth
year-on-year quarterly revenue growth declined by 58.5%, now sitting on 2.2m for the twelve trailing months.
more news about erytech pharma (eryp.pa).